April 30 (Reuters) - CSL Ltd (CSL) :
- ARS PHARMACEUTICALS SUBMITS RESPONSE FOR NEFFY® (EPINEPHRINE NASAL SPRAY) MARKETING AUTHORIZATION APPLICATION TO EMA’S CHMP AND ENTERS LICENSE AGREEMENT WITH CSL SEQIRUS FOR COMMERCIALIZATION OF NEFFY IN AUSTRALIA AND NEW ZEALAND
- ARS PHARMACEUTICALS INC: CHMP OPINION ON NEFFY MARKETING AUTHORIZATION APPLICATION ANTICIPATED IN Q2 OF 2024
News: CSL ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$283.04 |
Change
-3.910(1.36%) |
Mkt cap ! $136.6B | |||
| Open | High | Low | Value | Volume |
| $285.50 | $285.54 | $282.82 | $214.0M | 754.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $283.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $283.10 | 45 | 7 |
View Market Depth
| Last trade - 10.50am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$282.96 |
Change
-3.910 ( 1.30 %) |
||||
| Open | High | Low | Volume | ||
| $285.34 | $285.52 | $282.79 | 4037 | ||
| Last updated 11.10am 17/05/2024 ? | |||||
| CSL (ASX) Chart |